Reven Pharmaceuticals, Inc.
๐บ๐ธUnited States
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)โข Click on a phase to view related trials
Phase 1
3 (100.0%)Tolerability and Efficacy of RJX in Patients With COVID-19
Phase 1
- Conditions
- COVID-19Acute Respiratory Distress SyndromeSARS-CoV-2Hypoxemia
- Interventions
- Drug: Rejuveinix (RJX) Active ComparatorDrug: Placebo Comparator
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT04708340
- Locations
- ๐บ๐ธ
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
๐บ๐ธMemorial Hermann Southeast Hospital, Houston, Texas, United States
๐บ๐ธChristus Santa Rosa Hospital, New Braunfels, Texas, United States
A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT03680105
- Locations
- ๐บ๐ธ
ICON Early Phase Services, San Antonio, Texas, United States
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
Phase 1
- Conditions
- Critical Limb IschemiaPeripheral Arterial Disease
- Interventions
- Drug: Rejuveinix Low DoseDrug: Rejuveinix High Dose
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Reven Pharmaceuticals, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT03041259
News
No news found